Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Boston Scientific Corporation is a medical devices business based in the US. Boston Scientific Corporation shares (BSX) are listed on the NYSE and all prices are listed in US Dollars. Boston Scientific Corporation employs 38,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$43.25|
|52-week range||$32.99 - $46.29|
|50-day moving average||$44.37|
|200-day moving average||$42.91|
|Wall St. target price||$51.15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.37|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||0.21%|
|1 month (2021-09-16)||-3.67%|
|3 months (2021-07-16)||2.73%|
|6 months (2021-04-16)||5.72%|
|1 year (2020-10-15)||10.90%|
|2 years (2019-10-15)||12.45%|
|3 years (2018-10-15)||18.72%|
|5 years (2016-10-14)||88.45%|
Valuing Boston Scientific Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Boston Scientific Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Boston Scientific Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 117x. In other words, Boston Scientific Corporation shares trade at around 117x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Boston Scientific Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.567. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Boston Scientific Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Boston Scientific Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 billion.
The EBITDA is a measure of a Boston Scientific Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$11.2 billion|
|Operating margin TTM||16.1%|
|Gross profit TTM||$6.8 billion|
|Return on assets TTM||3.64%|
|Return on equity TTM||3.69%|
|Market capitalisation||$61.5 billion|
TTM: trailing 12 months
There are currently 20.5 million Boston Scientific Corporation shares held short by investors – that's known as Boston Scientific Corporation's "short interest". This figure is 22.2% up from 16.8 million last month.
There are a few different ways that this level of interest in shorting Boston Scientific Corporation shares can be evaluated.
Boston Scientific Corporation's "short interest ratio" (SIR) is the quantity of Boston Scientific Corporation shares currently shorted divided by the average quantity of Boston Scientific Corporation shares traded daily (recently around 5.9 million). Boston Scientific Corporation's SIR currently stands at 3.46. In other words for every 100,000 Boston Scientific Corporation shares traded daily on the market, roughly 3460 shares are currently held short.
However Boston Scientific Corporation's short interest can also be evaluated against the total number of Boston Scientific Corporation shares, or, against the total number of tradable Boston Scientific Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Boston Scientific Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Boston Scientific Corporation shares in existence, roughly 10 shares are currently held short) or 0.0145% of the tradable shares (for every 100,000 tradable Boston Scientific Corporation shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Boston Scientific Corporation.
Find out more about how you can short Boston Scientific Corporation stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Boston Scientific Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Boston Scientific Corporation's overall score of 29.23 (as at 12/31/2018) is nothing to write home about – landing it in it in the 57th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Boston Scientific Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.51/100
Social score: 12.87/100
Governance score: 7.87/100
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Boston Scientific Corporation scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Boston Scientific Corporation hasn't always managed to keep its nose clean.
|Total ESG score||29.23|
|Total ESG percentile||56.94|
|Level of controversy||3|
We're not expecting Boston Scientific Corporation to pay a dividend over the next 12 months.
Boston Scientific Corporation's shares were split on a 2:1 basis on 5 November 2003. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Boston Scientific Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Boston Scientific Corporation shares which in turn could have impacted Boston Scientific Corporation's share price.
Over the last 12 months, Boston Scientific Corporation's shares have ranged in value from as little as $32.99 up to $46.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Boston Scientific Corporation's is 0.8788. This would suggest that Boston Scientific Corporation's shares are less volatile than average (for this exchange).
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.